Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Phase 1 Completed 12 enrolled Boehringer Ingelheim

RandomizedCrossoverOpen-labelTreatment

Summary

Study to assess the amount of BIBR 953 ZW in urine and concentrations in plasma after administration of 50 mg of BIBR 1048 bid over three days each administered as two experimental formulations relative to drinking solution with and without coadministration of 40 mg Pantoprazole.

Timeline

Start: 2002-02
Primary completion: 2002-04
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran etexilate	Unknown	25 mg	Oral
Subject	Dabigatran etexilate	Unknown	50 mg	Oral
Subject	Pantoprazole	Other / unclassified	40 mg	—

Indications

No indication recorded.